Publikationsdatenbank

Histamine 2 receptor agonism and histamine 4 receptor antagonism ameliorate inflammation in a model of psoriasis (2020)

Art

Zeitschriftenartikel / wissenschaftlicher Beitrag

Autoren

Rossbach, Kristine

Wahle, Katharina

Bruer, Gustav

Brehm, Ralph

Langeheine, Marion

Rode, Kristina

Schaper-Gerhardt, Katrin

Gutzmer, Ralf

Werfel, Thomas

Kietzmann, Manfred

Bäumer, Wolfgang (WE 14)

Quelle

Acta dermato-venereologica

Bandzählung: 100

Heftzählung: 19

Seiten: adv00342

ISSN: 1651-2057

Sprache

Englisch

Verweise

URL (Volltext): https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-3674

DOI: 10.2340/00015555-3674

Pubmed: 33104231

Kontakt

Institut für Pharmakologie und Toxikologie

Koserstr. 20
14195 Berlin
+49 30 838 53221
pharmakologie@vetmed.fu-berlin.de

Abstract / Zusammenfassung

Psoriasis is a chronic inflammatory skin disorder characterized by hyperproliferative keratinocytes and immune cell infiltration into the skin, often accompanied by itch. Histamine, acting via histamine 1-4 receptors, is known to modulate immune responses in the skin and to induce itch. The aim of this study was to test the role of histamine 2 receptors and histamine 4 receptors in the imiquimod-induced psoriasis-like skin inflammation model. BALB/c mice were treated intraperitoneally with amthamine (histamine 2 receptor agonist), JNJ-39758979 (histamine 4 receptor antagonist), a combination of both, or vehicle twice daily in a preventive manner. Imiquimod was applied once daily onto the back skin for 10 consecutive days. Stimulation of histamine 2 receptors and blockade of histamine 4 receptors ameliorated imiquimod-induced skin inflammation. The combination of amthamine and JNJ-39758979 reduced skin inflammation even more pronounced, diminished epidermal hyperproliferation, and inhibited spontaneous scratching behaviour. A combination of histamine 2 receptor agonist and histamine 4 receptor antagonists could represent a new strategy for the treatment of psoriasis.